NZ597125A - Gpr119 agonists - Google Patents
Gpr119 agonistsInfo
- Publication number
- NZ597125A NZ597125A NZ597125A NZ59712510A NZ597125A NZ 597125 A NZ597125 A NZ 597125A NZ 597125 A NZ597125 A NZ 597125A NZ 59712510 A NZ59712510 A NZ 59712510A NZ 597125 A NZ597125 A NZ 597125A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- ylmethoxy
- methanesulfonyl
- piperidin
- tetrahydro
- Prior art date
Links
- 229940100607 GPR119 agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 abstract 2
- 101710163236 Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 2
- RDTBTUCYZYOHAM-UHFFFAOYSA-N 1-methylsulfonyl-4-[4-[[1-[[1-(trifluoromethyl)cyclopropyl]methyl]piperidin-4-yl]methoxy]phenyl]-3,6-dihydro-2h-pyridine Chemical compound C1N(S(=O)(=O)C)CCC(C=2C=CC(OCC3CCN(CC4(CC4)C(F)(F)F)CC3)=CC=2)=C1 RDTBTUCYZYOHAM-UHFFFAOYSA-N 0.000 abstract 1
- LAGIBLSAFMGIJY-UHFFFAOYSA-N 5-[[1-(2-fluoro-2-methylpropyl)piperidin-4-yl]methoxy]-2-(1-methylsulfonyl-3,6-dihydro-2h-pyridin-4-yl)pyridine Chemical group C1CN(CC(C)(F)C)CCC1COC1=CC=C(C=2CCN(CC=2)S(C)(=O)=O)N=C1 LAGIBLSAFMGIJY-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382114 | 2009-07-15 | ||
| US24544509P | 2009-09-24 | 2009-09-24 | |
| PCT/US2010/041645 WO2011008663A1 (en) | 2009-07-15 | 2010-07-12 | Gpr119 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597125A true NZ597125A (en) | 2013-08-30 |
Family
ID=43449712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597125A NZ597125A (en) | 2009-07-15 | 2010-07-12 | Gpr119 agonists |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8207344B2 (OSRAM) |
| EP (1) | EP2454251A1 (OSRAM) |
| JP (1) | JP5715127B2 (OSRAM) |
| KR (1) | KR101365854B1 (OSRAM) |
| CN (1) | CN102471313B (OSRAM) |
| AR (1) | AR077638A1 (OSRAM) |
| AU (1) | AU2010273642B2 (OSRAM) |
| BR (1) | BRPI1015921A2 (OSRAM) |
| CA (1) | CA2764906C (OSRAM) |
| CO (1) | CO6480977A2 (OSRAM) |
| CR (1) | CR20120012A (OSRAM) |
| DO (1) | DOP2012000006A (OSRAM) |
| EA (1) | EA020540B1 (OSRAM) |
| EC (1) | ECSP12011606A (OSRAM) |
| IL (1) | IL216776A0 (OSRAM) |
| MA (1) | MA33428B1 (OSRAM) |
| MX (1) | MX2012000704A (OSRAM) |
| NZ (1) | NZ597125A (OSRAM) |
| PE (1) | PE20121045A1 (OSRAM) |
| SG (1) | SG177646A1 (OSRAM) |
| TN (1) | TN2012000002A1 (OSRAM) |
| TW (1) | TWI429634B (OSRAM) |
| WO (1) | WO2011008663A1 (OSRAM) |
| ZA (1) | ZA201200227B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1599468E (pt) | 2003-01-14 | 2008-01-14 | Arena Pharm Inc | Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| JP5941916B2 (ja) | 2010-09-22 | 2016-06-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US20140018371A1 (en) * | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| AU2012240122B2 (en) | 2011-04-08 | 2016-08-25 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| WO2012170702A1 (en) * | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| EP2720544B1 (en) | 2011-06-16 | 2016-12-21 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| EP2760855B1 (en) * | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes |
| EP2771000B1 (en) | 2011-10-24 | 2016-05-04 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| WO2013062835A1 (en) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
| US9944600B2 (en) * | 2012-06-12 | 2018-04-17 | Chong Kun Dang Pharmaceutical Corp. | Piperidine derivatives for GPR119 agonist |
| WO2014052619A1 (en) * | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
| EP3074384B1 (en) | 2013-11-26 | 2019-05-22 | Chong Kun Dang Pharmaceutical Corp. | Amide derivatives for gpr119 agonist |
| KR101651505B1 (ko) * | 2014-05-02 | 2016-08-29 | 현대약품 주식회사 | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| DK3310760T3 (da) | 2015-06-22 | 2022-10-24 | Arena Pharm Inc | Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
| WO2021263039A1 (en) | 2020-06-26 | 2021-12-30 | Kallyope, Inc. | Ampk activators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1599468E (pt) * | 2003-01-14 | 2008-01-14 | Arena Pharm Inc | Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia |
| AU2007291252A1 (en) * | 2006-08-30 | 2008-03-06 | Inovacia Ab | Pyridine compounds for treating GPR119 related disorders |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CN101801954B (zh) | 2007-09-20 | 2013-10-09 | Irm责任有限公司 | 作为gpr119活性调节剂的化合物和组合物 |
-
2010
- 2010-07-06 AR ARP100102424A patent/AR077638A1/es not_active Application Discontinuation
- 2010-07-08 TW TW099122534A patent/TWI429634B/zh not_active IP Right Cessation
- 2010-07-12 AU AU2010273642A patent/AU2010273642B2/en not_active Ceased
- 2010-07-12 BR BRPI1015921A patent/BRPI1015921A2/pt not_active IP Right Cessation
- 2010-07-12 SG SG2012002523A patent/SG177646A1/en unknown
- 2010-07-12 NZ NZ597125A patent/NZ597125A/xx not_active IP Right Cessation
- 2010-07-12 KR KR1020127000996A patent/KR101365854B1/ko not_active Expired - Fee Related
- 2010-07-12 JP JP2012520691A patent/JP5715127B2/ja not_active Expired - Fee Related
- 2010-07-12 WO PCT/US2010/041645 patent/WO2011008663A1/en not_active Ceased
- 2010-07-12 PE PE2012000041A patent/PE20121045A1/es not_active Application Discontinuation
- 2010-07-12 MA MA34531A patent/MA33428B1/fr unknown
- 2010-07-12 US US12/834,054 patent/US8207344B2/en not_active Expired - Fee Related
- 2010-07-12 EA EA201270169A patent/EA020540B1/ru not_active IP Right Cessation
- 2010-07-12 CN CN201080031375.4A patent/CN102471313B/zh not_active Expired - Fee Related
- 2010-07-12 MX MX2012000704A patent/MX2012000704A/es active IP Right Grant
- 2010-07-12 EP EP10734412A patent/EP2454251A1/en not_active Withdrawn
- 2010-07-12 CA CA2764906A patent/CA2764906C/en not_active Expired - Fee Related
-
2011
- 2011-12-05 IL IL216776A patent/IL216776A0/en unknown
- 2011-12-29 CO CO11181048A patent/CO6480977A2/es active IP Right Grant
-
2012
- 2012-01-02 TN TNP2012000002A patent/TN2012000002A1/en unknown
- 2012-01-09 CR CR20120012A patent/CR20120012A/es unknown
- 2012-01-11 DO DO2012000006A patent/DOP2012000006A/es unknown
- 2012-01-11 ZA ZA2012/00227A patent/ZA201200227B/en unknown
- 2012-01-13 EC EC2012011606A patent/ECSP12011606A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL216776A0 (en) | 2012-03-01 |
| TN2012000002A1 (en) | 2013-09-19 |
| CA2764906A1 (en) | 2011-01-20 |
| TWI429634B (zh) | 2014-03-11 |
| PE20121045A1 (es) | 2012-08-09 |
| CO6480977A2 (es) | 2012-07-16 |
| CA2764906C (en) | 2014-06-10 |
| EA020540B1 (ru) | 2014-11-28 |
| CR20120012A (es) | 2012-03-28 |
| WO2011008663A1 (en) | 2011-01-20 |
| MA33428B1 (fr) | 2012-07-03 |
| ECSP12011606A (es) | 2012-02-29 |
| AU2010273642A1 (en) | 2012-01-19 |
| CN102471313B (zh) | 2014-06-04 |
| AU2010273642B2 (en) | 2014-03-13 |
| SG177646A1 (en) | 2012-02-28 |
| MX2012000704A (es) | 2012-03-07 |
| KR101365854B1 (ko) | 2014-02-21 |
| EA201270169A1 (ru) | 2012-06-29 |
| DOP2012000006A (es) | 2012-01-31 |
| JP2012533546A (ja) | 2012-12-27 |
| AR077638A1 (es) | 2011-09-14 |
| US8207344B2 (en) | 2012-06-26 |
| BRPI1015921A2 (pt) | 2016-04-26 |
| CN102471313A (zh) | 2012-05-23 |
| JP5715127B2 (ja) | 2015-05-07 |
| EP2454251A1 (en) | 2012-05-23 |
| TW201114757A (en) | 2011-05-01 |
| US20110015199A1 (en) | 2011-01-20 |
| KR20120024964A (ko) | 2012-03-14 |
| ZA201200227B (en) | 2013-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597125A (en) | Gpr119 agonists | |
| MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
| MY148470A (en) | Indole derivatives as s1p1 receptor agonists | |
| NZ603876A (en) | Nitrogen heterocyclic compounds useful as pde10 inhibitors | |
| ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
| NO20084307L (no) | Heterocykliske GPCR agonister | |
| ATE557023T1 (de) | Piperidinylverbindungen als gpcr-agonisten | |
| NZ630488A (en) | Piperidine derivatives for gpr119 agonist | |
| NZ581698A (en) | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | |
| MX2012002366A (es) | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. | |
| DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| EA200870474A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| WO2007116230A8 (en) | Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists | |
| ZA200808816B (en) | Pieridinyl substituted pyrrolidinones as inhibitors of 11-Beta-hydroxysteroid dehydrogenase 1 | |
| UA95798C2 (ru) | Производные циклогексилпиразоллактама как ингибиторы 11-бета-гидроксистероиддегидрогеназы 1 | |
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| DK2114933T3 (da) | Piperidin-GPCR-agonister | |
| NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
| MX2010003760A (es) | Derivados de n-(pirazol-3-il)-benzamida como activadores de glucocinasa. | |
| ZA200710645B (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| EP2257543A4 (en) | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, PROCESSING METHODS AND PREPARATION METHODS THEREOF | |
| GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
| UA101172C2 (ru) | Бициклозамещенные пиразолоназопроизводные, способ их получения и фармацевтическое применение | |
| WO2010052144A3 (en) | Neuropeptide-2-receptor (y-2r) agonists and uses thereof | |
| NZ597668A (en) | Novel gpr 119 agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |